Sponsored Links

Delcath Systems Incorporated

News and Blogs

Total : 30 View more »

Delcath Systems Granted Orphan-Drug Designations for Cutaneous and Ocular Melanoma (PR Newswire)

biz.yahoo.com | Nov 18, 2008

Delcath Systems Granted Orphan-Drug Designations for Cutaneous and Ocular Melanoma. - NEW YORK, Nov. 18 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH - News), a medical technology company testing its proprietary liver cancer treatment for melanoma metastatic to the liver, announced

http://biz.yahoo.com/prnews/081118/ny46990.html?.v=1

Delcath Systems Appoints Eamonn Hobbs to Board of Directors (Marketwire)

us.rd.yahoo.com | Oct 15, 2008

Delcath Systems Appoints Eamonn Hobbs to Board of Directors. - NEW YORK, NY--(MARKET WIRE)--Oct 15, 2008 -- Delcath Systems, Inc. (NasdaqCM:DCTH - News) today announced the appointment of Mr.

http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/iw/081015/0443051.html

Delcath Systems to Take on Onyx Pharma's Nexavar (at Seeking Alpha)

seekingalpha.com | Jun 20, 2008

Nexavar was recently approved by the FDA for the indication of primary liver cancer and is co-developed by Onyx Pharmaceuticals (ONXX) and pharma giant Bayer.

http://seekingalpha.com/article/82048-delcath-systems-to-take-on-onyx-pharma-s-nexavar?source=yahoo

Web Sites

Total : 75 View more »

DCTH: Conference call regarding to Host Quarterly Update Conference Call @ 16:30 ET Today [delayed]

www.zibb.com

Delcath Systems Inc (Nasdaq SC : DCTH) will host a conference call regarding to Host Quarterly Update Conference Call. Call Details When : Wednesday, September 10, 2008 Webcast : Click Here to Listen Phone # : 304-345-7506 Passcode : 279838 Replay Information Phone # : 402-970-2661 Passcode :

http://www.zibb.com/article/3937542/DCTH+Conference+call+regarding+to+Host+Quarterly+Update+Conference+Call+ET+Today+delayed

Delcath Systems, Inc.

Delcath has developed a system to isolate organs from the general circulatory system. The first application of this technology is used to administer chemotherapy and other therapeutic agents directly to the liver.

http://www.delcath.com/

Delcath Systems Drug-Delivery Company Profile (market briefing)

Delcath has developed a system to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver.

http://www.biz-lib.com/ZEB67457.html

Delcath Systems (DCTH) News - Company News and Press Releases

Track Any Stock Instantly Just enter up to ten of your stocks in the Stock Tracker box, click the ADD button beside any of Today's Hot Stocks, or click ADD beside any of the stocks you've Recently Viewed.

http://www.investorguide.com/stock-news.cgi?ticker=DCTH

 

Delcath Systems' President and CEO Richard Taney to Present at Two Medical Technology Conferences -

Delcath Systems, Inc. (NASDAQ: DCTH) a leading developer of regional therapy for liver cancer announced today that President and CEO Richard Taney will participate in a Panel Discussion on "Combination Products: A Convergence of Technologies and Market Opportunities" at the Medical Device & Manufacturing Conference, Oct 22, 2008, 12:30pm-1:15pm at the Minneapolis Convention Center. Mr. Taney will also be making a presentation on the Delcath PHP technology at the Investment in Innovation (In3) East Conference to be held on October 23rd, 9:30am-10:00am at the Westin Copley Place in Boston.

About Delcath Systems, Inc.

Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

Company Contact:
Delcath Systems, Inc.
Richard Taney
(212) 489-2100
Email Contact

Investor Relations Contact:
Strategic Growth International, Inc.
Richard E. Cooper
(212) 838-1444
Email Contact

Public Relations Contact:
Rubenstein Associates, Inc.
Robin Wagge
(212) 843-8006
Email Contact


SOURCE: Delcath Systems, Inc.

http://www2.marketwire.com/mw/emailprcntct?id=A6C1ADC7C5182DA0
http://www2.marketwire.com/mw/emailprcntct?id=2680952DAB30926D
http://www2.marketwire.com/mw/emailprcntct?id=68071DB41F5658EE

Read more...

Tags: asia   canada   cancer   ceo   clinical   conference   drugs   email   europe   manufacturing   market   medical   nasdaq   president   products   property   public relations   research   securities   technology  

Companies: Delcath Systems, Inc. (DCTH)

Permalink

 

Investigator Presents on Delcath Systems Phase III Trial Experience - Zibb.com

Delcath Systems, Inc. (NASDAQ: DCTH) reported that the Adjunct Principal Investigator for its Phase III clinical trial, James Pingpank, Jr., MD, discussed interim results from its randomized study of high-dose melphalan, delivered via the Company's Percutaneous Hepatic Perfusion (PHP) system, in patients with inoperable liver metastases from melanoma. Dr. Pingpank's presentation entitled "Targeted Chemotherapy: Minimally Invasive Percutaneous Hepatic Perfusion" was made on Saturday, October 4 at the "Perspectives in Melanoma XII" Meeting in The Hague, The Netherlands.

During his presentation at this prestigious conference, Dr. Pingpank stated: "The results that we have seen to date are tracking the response rates that we observed in the phase I trial of patients treated for metastatic melanoma in the liver with Percutaneous Hepatic Perfusion." Dr. Pingpank also discussed early results from the melanoma arm of the Company's Phase II trial, which is limited to patients who had previously received surgical isolated regional delivery of melphalan. Dr. Pingpank reported: "Of the five patients treated to date in the Phase II melanoma trial, we have observed a 100% response rate. All of these are durable partial responses."

Dr. Pingpank treated the largest number of patients in Delcath's Phase III Trial while at the National Cancer Institute (NCI). This ongoing study was recently expanded to include ten leading cancer centers throughout the United States. The Phase III trial of 92 patients is comparing Progression Free Survival (PFS) in patients treated with the Delcath PHP System to a control arm receiving Best Available Care (BAC). Following completion of the Phase I trial in 2003, the FDA granted Fast Track review status and advanced the Phase I trial directly to the Phase III trial. The trial, which is governed by a Special Protocol Assessment (SPA) with the FDA, seeks to demonstrate responses in PHP patients of at least 7.8 months, versus an expected response of four months or less in patients receiving BAC.

About Delcath Systems, Inc.

Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company has developed a proprietary, patented system which will improve the efficacy of cancer treatment while reducing the considerable, systemic side-effects of chemotherapy. Delcath's novel drug delivery platform is capable of delivering anti-cancer drugs at very high doses to a specific organ or region of the body while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.

This release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the current belief of management. These statements relate to, among other things, the results to date of our phase III clinical trials as described above. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things: risks that any results of any trials to date are interim and may not be borne out or supported by subsequent or final results or that any such trials may not be fully completed as necessary; risks relating to our ability to further advance the development of the our system in clinical trials; risks of any failure to comply with regulations relating to our system, including FDA requirements; risks of failure to obtain the financial resources to complete development of our system; the risk that the FDA may interpret the results of our studies differently from any interpretation we may have; the risk that Dr. Pingpank's discussion as described above or elsewhere does not necessarily represent the position of or any information on behalf of Delcath, since he is not an employee, consultant or agent of or otherwise authorized to speak on behalf of Delcath, and all of the other risks discussed from time to time in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

Company Contact:
Delcath Systems, Inc.
Richard Taney
(212) 489-2100
Email Contact

Investor Relations Contact:
Strategic Growth International, Inc.
Richard E. Cooper
Cass Almendral
(212) 838-1444
Email Contact
Email Contact

Public Relations Contact:
Rubenstein Associates, Inc.
Robin Wagge
(212) 843-8006
Email Contact


SOURCE: Delcath Systems, Inc.

http://www2.marketwire.com/mw/emailprcntct?id=212D87D392A18D73
http://www2.marketwire.com/mw/emailprcntct?id=E8FA9CD29CC4ED19
http://www2.marketwire.com/mw/emailprcntct?id=378A0FD30C3275E4
http://www2.marketwire.com/mw/emailprcntct?id=91BD3372E6597E64

Read more...

Tags: annual report   asia   canada   cancer   clinical   conference   consultant   drugs   email   europe   fda   medical   nasdaq   property   public relations   rates   regulations   securities   technology   track   trial  

Companies: Delcath Systems, Inc. (DCTH)

Permalink

 

Delcath Systems to Host Quarterly Update Conference Call - Zibb.com

Delcath Systems, Inc. (NASDAQ: DCTH) announced today that the Company will host a quarterly update conference call. Richard Taney, President and Chief Executive Officer of Delcath Systems, will host the call beginning at 4:30 pm Eastern Time on Wednesday, September 10, 2008. During the call, Mr. Taney will discuss recent progress made regarding the rollout of clinical studies and the Company's ongoing strategy for increasing the enrollment program over the near term. A question and answer session will immediately follow management's prepared remarks.

The conference call will be webcast and may be accessed by visiting Delcath Systems' website at www.delcath.com. A replay of the audio webcast will be available on the Company's website starting shortly after the call on September 10, 2008.

Those parties interested in participating in the live call may join by dialing (304) 345-7506 in the U.S. and referencing conference identification number 279838. A telephone replay will be available at 7:30 pm EDT the day of the live call and can be accessed by dialing (402)970-2661 in the U.S and referencing conference identification number 100539. The replay will be available until Wednesday, September 24, 2008 until 7:30 pm EDT.

About Delcath Systems, Inc.

Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company has developed a proprietary, patented system which will improve the efficacy of cancer treatment while reducing the considerable, systemic side-effects of chemotherapy. Delcath's novel drug delivery platform is capable of delivering anti-cancer drugs at very high doses to a specific organ or region of the body while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

Company Contact:
Delcath Systems, Inc.
Richard Taney
(212) 489-2100
Email Contact

Investor Relations Contact:
Strategic Growth International, Inc.
Richard E. Cooper/Cass Almendral
(212) 838-1444
Email Contact
Email Contact

Public Relations Contact:
Rubenstein Associates, Inc.
Robin Wagge
(212) 843-8006
Email Contact


SOURCE: Delcath Systems, Inc.

http://www2.marketwire.com/mw/emailprcntct?id=57F68137D094131C
http://www2.marketwire.com/mw/emailprcntct?id=E7777631D91F919E
http://www2.marketwire.com/mw/emailprcntct?id=5EFD1C47A00E9CFB
http://www2.marketwire.com/mw/emailprcntct?id=D94FC5DA4B4CF04B

Read more...

Tags: asia   canada   cancer   ceo   clinical   conference   drugs   email   europe   medical   nasdaq   president   property   public relations   research   securities   technology  

Companies: Delcath Systems, Inc. (DCTH)

Permalink

 

Delcath Systems Targeted Drug Delivery Technology to Be Presented at Western Angiographic and

Delcath Systems, Inc. (NASDAQ: DCTH), a leading developer of regional therapy for cancer, today announced that Dr. Charles Nutting of Swedish Medical Center in Englewood, Colorado will deliver a presentation at the 38th Annual Meeting of the Western Angiographic and Interventional Society ("WAIS"). Dr. Nutting will discuss his involvement with Delcath's Phase III trial of its Percutaneous Hepatic Perfusion (PHP) System for the treatment of inoperable metastatic melanoma at the conference, held in Maui, Hawaii from September 20-25, 2008.

Dr. Nutting, a Principal Investigator on the Phase III trial, will present Delcath's PHP technology and its role in the treatment of liver metastases. Dr. Nutting has been at the forefront of regional therapy for the treatment of cancer, and is a leader in the field of interventional oncologic techniques. He has recently joined the Delcath trial, as the Principal Investigator at Swedish Medical Center, one of the nine enrolling centers for the randomized Phase III trial.

"Dr. Nutting's presentation marks an expansion in awareness for the Delcath PHP System," stated Richard L. Taney, President and CEO of Delcath. "This is the first major presentation regarding the Phase III trial by an Investigator outside of the National Cancer Institute. As the oncology community becomes more familiar with the potential benefits of Delcath's PHP technology, this presentation will further the awareness of the Interventional Radiology Community which will be a key driver in the adoption of this unique treatment for inoperable cancers."

WAIS is a regional society of leading physicians from the western states and Canada dedicated to vascular and interventional radiology, and image-guided techniques for the diagnosis and treatment of cancer and other illnesses. Information on this organization and conference can be found at www.westernangio.org.

About Delcath Systems, Inc.

Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company has developed a proprietary, patented system which will improve the efficacy of cancer treatment while reducing the considerable, systemic side-effects of chemotherapy. Delcath's novel drug delivery platform is capable of delivering anti-cancer drugs at very high doses to a specific organ or region of the body while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

Company Contact:
Delcath Systems, Inc.
Richard Taney
(212) 489-2100
Email Contact

Investor Relations Contact:
Strategic Growth International, Inc.
Richard E. Cooper/Cass Almendral
(212) 838-1444
Email Contact
Email Contact

Public Relations Contact:
Rubenstein Associates, Inc.
Robin Wagge
(212) 843-8006
Email Contact


SOURCE: Delcath Systems, Inc.

http://www2.marketwire.com/mw/emailprcntct?id=37A3E7D4D650407C
http://www2.marketwire.com/mw/emailprcntct?id=48CCFBA4EA343527
http://www2.marketwire.com/mw/emailprcntct?id=258B6A608761474C
http://www2.marketwire.com/mw/emailprcntct?id=D825E133C9D3CC94

Read more...

Tags: asia   canada   cancer   ceo   clinical   colorado   community   conference   drugs   email   europe   expansion   hawaii   medical   nasdaq   physicians   president   property   public relations   research   securities   technology   trial  

Companies: Delcath Systems, Inc. (DCTH)

Permalink

 

News from Zibb.com

Explore Related Products

Explore in Related Industries

Explore Related Topics

Events

1 more »